Compounds and methods for treating urinary incontinence

Use of phenylaminoimidazolines of general formula Ib

• 18
• wherein R1, R2, R3, R4 and R5 denote, independently of one another:
• hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy, halogen, —CF3, —OCF3 or —NR6R7 wherein
• R6 denotes hydrogen, C3-6-cycloalkyl, C1-6-alkyl or C2-4-acyl,
• R7 denotes hydrogen, C3-6-cycloalkyl, C1-6-alkyl or C2-4-acyl;
• or
• R6 and R7 together with the nitrogen atom form a 5- or 6-membered saturated or unsaturated ring which may contain up to two additional heteroatoms from the group comprising oxygen, sulphur or nitrogen, whilst each additional nitrogen atom may be substituted by C1-4-alkyl;
• or
• R6 and R7 together with the nitrogen atom form phthalimido;
• or
• R1 and R2 together form a fused pyrazole of the formula
• 19
• wherein R8 is C1-3-alkyl,
• or a fused thiadiazole of the formula
• 20
• wherein R3, R4 and Rs are as hereinbefore defined, and the pharmacologically acceptable acid addition salts thereof, for preparing pharmaceutical composition for treating urinary incontinence, particularly stress incontinence.

New phenyliminoimidazolidines of general formula II

• 27
• wherein
• R1 denotes hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy, halogen, —CF3 or —OCF3;
• R2 denotes —NR6R7 wherein
• R6 is hydrogen, C3-6-cycloalkyl, C1-6-alkyl, C2-4-acyl,
• R7 is hydrogen, C3-6-cycloalkyl, C1-6-alkyl, C2-4-acyl, or
• R6 and R7 together with the nitrogen atom form a 5- or 6-membered saturated or unsaturated ring which may contain up to two further heteroatoms from the group comprising oxygen, sulphur or nitrogen, whilst each additional nitrogen atom may be substituted by C1-4-alkyl, preferably methyl;
• or R6 and R7 together with the nitrogen atom form phthalimido;
• R3 denotes hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, —CF3 or —OCF3;
• R4 denotes hydrogen, C1-6-alkyl or halogen;
• R5 denotes hydrogen, C1-6-alkyl, C1-6-alkoxy, halogen, —CF3 or —OCF3,
• and the pharmacologically acceptable acid addition salts thereof, with the exception of 2-(3-diethylamino-2-methyl)-imidazolidine.